Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Accumulated Expenses (2016 - 2020)

Historic Other Accumulated Expenses for Akebia Therapeutics (AKBA) over the last 5 years, with Q1 2020 value amounting to $10.3 million.

  • Akebia Therapeutics' Other Accumulated Expenses fell 3937.98% to $10.3 million in Q1 2020 from the same period last year, while for Mar 2020 it was $10.3 million, marking a year-over-year decrease of 3937.98%. This contributed to the annual value of $9.5 million for FY2019, which is 2096.51% down from last year.
  • Akebia Therapeutics' Other Accumulated Expenses amounted to $10.3 million in Q1 2020, which was down 3937.98% from $9.5 million recorded in Q4 2019.
  • In the past 5 years, Akebia Therapeutics' Other Accumulated Expenses registered a high of $16.9 million during Q1 2019, and its lowest value of $1.3 million during Q1 2016.
  • For the 5-year period, Akebia Therapeutics' Other Accumulated Expenses averaged around $5.9 million, with its median value being $3.2 million (2018).
  • In the last 5 years, Akebia Therapeutics' Other Accumulated Expenses soared by 42561.32% in 2019 and then plummeted by 3937.98% in 2020.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Other Accumulated Expenses stood at $1.9 million in 2016, then rose by 21.74% to $2.4 million in 2017, then skyrocketed by 410.0% to $12.1 million in 2018, then fell by 20.97% to $9.5 million in 2019, then rose by 7.48% to $10.3 million in 2020.
  • Its last three reported values are $10.3 million in Q1 2020, $9.5 million for Q4 2019, and $8.8 million during Q3 2019.